Remedy, a company specializing in medical imaging equipment, was listed on the KOSDAQ market on the 13th, officially beginning stock market trading. As of 9:00 a.m. that day, the stock price stood at 30,250 won, up 46.13% from the initial public offering price of 20,700 won.

Remedy supplies portable X-ray solutions for medical and industrial use based on its proprietary X-ray core technology. The company possesses independent low-dose X-ray generation technology and a control platform, and develops and manufactures digital medical X-ray imaging devices and industrial non-destructive testing (NDT) equipment. A key feature is the enhanced mobility and portability that complement the limitations of existing fixed-type equipment.

■ Flagship Products: KA6 and XCAM Series

The company's flagship products are the KA6 and XCAM series, both digital medical X-ray imaging devices. The equipment is designed to be compact and lightweight while still producing clear images even in low-dose environments. They are currently utilized in medical settings such as emergency care, disaster response, mobile health screenings, home visits, and public healthcare services.

In the industrial sector, the company supplies non-destructive testing equipment, targeting the safety inspection market for manufacturing facilities, plants, and various industrial installations. Non-destructive testing technology, which identifies internal flaws without damaging the object being inspected, is regarded as a critical technology that enhances inspection efficiency at industrial sites. It is applied across various fields, including industrial facility maintenance and structural safety diagnostics.

■ IPO Proceeds to Be Invested in R&D, Production Expansion, and Overseas Expansion

Remedy has built a business portfolio that simultaneously targets both the medical and industrial X-ray markets. The company's strategy is to use the funds raised through its KOSDAQ listing to expand research and development, increase production capacity, and enter overseas markets, thereby strengthening its foundation for growth.

The company previously attracted significant interest during the IPO process. The demand forecast for institutional investors recorded a competition ratio of 1,146.41 to 1, while the general public subscription competition ratio reached 1,706.71 to 1. The final offering price was set at 20,700 won, the upper end of the desired price range.

Following the listing, investor attention is now focused on the stock's price trajectory.

[※ This article was written with the assistance of AI. It is based on publicly available market information during trading hours, and stock prices and market conditions are subject to real-time fluctuations. Investment decisions should be made carefully at the investor's own discretion after directly verifying the latest disclosures and market prices. This publication assumes no legal or financial responsibility.]